Home › Arrhythmia › NCT04685317
Safety and Efficacy of the Sentinel Cerebral Protection Device in Atrial Fibrillation Ablation
A Pilot Randomized Study of the Use of The Sentinel Device for Cerebral Protection During Atrial Fibrillation Ablation
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Men / women over the age of 18 years undergoing radiofrequency, pulsed field or cryo-balloon ablation for AF in accordance with the current AHA/ACC/HRS guideline for management of patients with atrial fibrillation. This includes patients with symptomatic paroxysmal, persistent or long-standing persistent AF not responsive to or intolerant of a Class I or III anti-arrhythmic drug or patients with symptomatic paroxysmal or persistent AF prior to the initiation of a Class I or Class III antiarrhythmic drug). The decision to perform catheter ablation for AF will be made by the treating provider and the patient in accordance with the guidelines noted above. (January et al. J Am Coll Cardiol vol. 64, No. 21, 2014, page e1) * Able to provide informed consent. * Patients should have acceptable aortic arch anatomy and vessel diameters without significant stenosis as assessed using pre-procedure CT angiogram. Exclusion Criteria: * Anatomy unsuitable for use of Sentinel device: * Right extremity vasculature not suitable due to compromised arterial blood flow. * Brachiocephalic, left carotid or aortic arch not suitable due to excessive tortuosity, significant ectasia, stenosis (\>70%), dissection or aneurysm. * Cerebrovascular accident or transient ischemic attack within six months * Carotid disease requiring treatment within six weeks * Unable or unwilling to provide informed consent. * Pregnant women * Known history of dementia. * Known hypersensitivity to nickel-titanium. * Presence of MRI non-compatible implanted devices including cardiac implantable electronic devices. * The presence of left atrial thrombus. All patients routinely undergo transesophageal echocardiogram prior to ablation and / or intra-cardiac echocardiogram at the beginning of the ablation procedure to rule out the presence of left atrial thrombus. * Patients with a reversible cause for AF such as hyperthyroidism.
About the study
The purpose of the study is to see if the Sentinel® Cerebral Protection System may prevent occurrence of stroke during an ablation procedure for atrial fibrillation (AF). The secondary purpose of this study is to study if cognitive function after AF ablation differs between those treated with the Sentinel cerebral protection device and those who do not receive the device.
What is being tested
- Sentinel® Cerebral Protection System (device)
- Magnetic Resonance Imaging (diagnostic test)
Sponsor: Malini Madhavan · Participants: 48 · Started: Mar 7, 2023
Contact the study team
- Joseph Abdel Messih · Phone: 507-422-3967
Official record on ClinicalTrials.gov — NCT04685317
Locations in the U.S.
| Minnesota | Mayo Clinic in Rochester, Rochester |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.